SCHEMBL589336

SCHEMBL589336

NC(=O)c1cc(S(=O)(=O)c2ccccc2)ccc1[N+](=O)[O-]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
KIF18A Q8NI77 1/20 0.47
ABCC9 O60706 1/20 0.46
ABCC8 Q09428 1/20 0.46
KCNJ11 Q14654 1/20 0.46
KCNJ8 Q15842 1/20 0.46
GAA P10253 3/20 0.45
HTT P42858 2/20 0.45
RAB9A P51151 2/20 0.44
MEN1 O00255 1/20 0.44
PDE4B Q07343 1/20 0.44
VCAM1 P19320 1/20 0.44
ALDH1A1 P00352 3/20 0.44
NPC1 O15118 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NOD1 Q9Y239 1/20 0.44
MAPT P10636 2/20 0.43
MAPK1 P28482 2/20 0.43
S1PR4 O95977 1/20 0.43
S1PR1 P21453 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6564232 0.88 DTYMK (0.54) KMT2AKIF18AABCC9ABCC8KCNJ11
SCHEMBL11815819 0.81 CA2 (0.60) VCAM1ALDH1A1MAPTPOLBCA12
SCHEMBL8625649 0.80 ABCC9 (0.45) KMT2AKIF18AABCC9ABCC8KCNJ11
SCHEMBL27506162 0.79 KMT2A (0.47) KMT2AKIF18AABCC9ABCC8KCNJ11
SCHEMBL2903871 0.78 KMT2A (0.56) KMT2AKIF18AABCC9ABCC8KCNJ11
SCHEMBL11490967 0.78 KMT2A (0.56) KMT2AKIF18AGAAHTTRAB9A
SCHEMBL589632 0.78 IKBKB (0.56) GAAPDE4BALDH1A1SMN1; SMN2MAPT
SCHEMBL16573454 0.78 MAPT (0.42) KMT2AGAAHTTMEN1ALDH1A1
SCHEMBL6567534 0.77 ABCC9 (0.45) KMT2AKIF18AABCC9ABCC8KCNJ11
SCHEMBL28674925 0.75 KIF18A (0.59) KMT2AKIF18AABCC9ABCC8KCNJ11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101594862-B Substituted indazole derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-11-25 CN disclosed
EP-2120932-B1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES SRL (IT) 2014-07-09 EP disclosed
US-8114865-B2 Indazole derivatives as kinase inhibitors for the treatment of cancer NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-14 US disclosed
US-20100197665-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-08-05 US disclosed
CN-101594862-A Substituted indazole derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES SRL (IT) 2009-12-02 CN disclosed
EP-2120932-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER Nerviano Medical Sciences S.r.l. (IT) 2009-11-25 EP disclosed
WO-2008074749-A9 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES SRL (IT) 2009-05-07 WO disclosed
WO-2008074749-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197665-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER MAP3K5, MAP3K19, MAP3K3 KMT2A 1074/4885KIF18A 1226/4885ABCC9 1789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.